Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results, Beats Expectations By $0.15 EPS

Puma Biotechnology (NASDAQ:PBYI) announced its earnings results on Thursday. The biopharmaceutical company reported $0.19 earnings per share for the quarter, beating analysts’ consensus estimates of $0.04 by $0.15, FiscalAI reports. Puma Biotechnology had a net margin of 11.50% and a return on equity of 21.34%. The business had revenue of $56.50 million for the quarter, compared to the consensus estimate of $53.00 million.

Here are the key takeaways from Puma Biotechnology’s conference call:

• NERLYNX revenue and demand improved: Q2 net product revenue rose to $53.6 million from $42.0 million in Q1 and $49.2 million a year ago, while U.S. demand increased 8% sequentially and 11% year over year. Management raised full-year 2026 net product revenue guidance to $205–$209 million.
• Puma reported Q2 GAAP net income of $8.2 million, reversing a $3.8 million loss in Q1, and raised full-year net income guidance to $17–$20 million. The company also made its final $11.1 million loan payment and is now debt-free.
• Alisertib development is progressing, with ALISCA-Breast1 enrollment being narrowed to the 40 mg and 50 mg dose groups and ALISCA-Lung1 now enrolling at 70 mg twice daily. Puma expects to start the combination trial ALISCA-Lung02 in Q3 and provide additional trial data in 2027.
• New prescriptions for NERLYNX declined 6% sequentially, and the company expects higher 2026 R&D spending, up 34%–37% year over year, as clinical trials advance. Q3 net income guidance of $2–$2.5 million is substantially below Q2’s result.
• Full-year royalty guidance was reduced to $19–$22 million from $20–$23 million, partly reflecting a possible late-2026 or 2027 reduction in China royalties if generic NERLYNX reaches a specified market-share threshold.

Puma Biotechnology Stock Performance

Shares of PBYI stock traded up $0.79 on Friday, hitting $8.91. 683,217 shares of the company’s stock traded hands, compared to its average volume of 315,645. Puma Biotechnology has a one year low of $3.05 and a one year high of $9.40. The company’s fifty day simple moving average is $7.80 and its 200 day simple moving average is $7.18. The stock has a market capitalization of $453.51 million, a price-to-earnings ratio of 17.13 and a beta of 1.22.

More Puma Biotechnology News

Here are the key news stories impacting Puma Biotechnology this week:

• Positive Sentiment: Second-quarter results exceeded expectations. Puma reported earnings of $0.19 per share, above the $0.04 consensus estimate, while revenue reached $56.5 million versus expectations of $53.0 million. Profitability included a 10.69% net margin and 20.30% return on equity. Puma Biotechnology Q2 2026 earnings results
• Positive Sentiment: Full-year 2026 revenue guidance was raised. Puma now expects revenue of $224 million to $231 million, above the approximately $222.5 million analyst consensus. Rising Nerlynx sales and planned milestones for the alisertib program provide additional potential catalysts. PBYI Q2 earnings and raised guidance
• Neutral Sentiment: Management’s outlook was mixed for the next quarter. Third-quarter revenue guidance of $56 million to $59 million is slightly below the $59.4 million consensus estimate, suggesting that near-term growth may be more modest despite the improved full-year outlook. Puma Biotech Q2 earnings and revenue results
• Negative Sentiment: TD Cowen remains cautious. The firm raised its price target from $5 to $6 but maintained a “hold” rating. The revised target still implies roughly 32.7% downside from the referenced $8.91 share price, potentially weighing on investor sentiment after the recent advance. TD Cowen raises Puma Biotechnology price target

Analyst Ratings Changes

PBYI has been the topic of a number of research analyst reports. Wall Street Zen lowered shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 16th. Weiss Ratings lowered shares of Puma Biotechnology from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Finally, TD Cowen increased their target price on Puma Biotechnology from $5.00 to $6.00 and gave the company a “hold” rating in a research note on Friday. Two investment analysts have rated the stock with a Hold rating, According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $6.00.

Insider Buying and Selling

In other Puma Biotechnology news, Director Troy Edward Wilson sold 10,800 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $7.20, for a total value of $77,760.00. Following the completion of the sale, the director directly owned 59,750 shares of the company’s stock, valued at $430,200. The trade was a 15.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jay M. Moyes sold 22,000 shares of the company’s stock in a transaction dated Friday, June 12th. The shares were sold at an average price of $7.22, for a total transaction of $158,840.00. Following the sale, the director owned 58,322 shares of the company’s stock, valued at approximately $421,084.84. The trade was a 27.39% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 132,028 shares of company stock worth $1,006,711 over the last 90 days. Insiders own 22.20% of the company’s stock.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors have recently bought and sold shares of the stock. Dimensional Fund Advisors LP increased its stake in Puma Biotechnology by 5.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,339,603 shares of the biopharmaceutical company’s stock worth $7,971,000 after purchasing an additional 67,725 shares during the period. O Shaughnessy Asset Management LLC boosted its stake in shares of Puma Biotechnology by 35.3% during the fourth quarter. O Shaughnessy Asset Management LLC now owns 1,120,329 shares of the biopharmaceutical company’s stock valued at $6,666,000 after purchasing an additional 292,108 shares during the period. Geode Capital Management LLC grew its holdings in shares of Puma Biotechnology by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 994,345 shares of the biopharmaceutical company’s stock worth $5,917,000 after purchasing an additional 10,823 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of Puma Biotechnology by 4,823,365.0% in the third quarter. Russell Investments Group Ltd. now owns 964,693 shares of the biopharmaceutical company’s stock worth $5,123,000 after purchasing an additional 964,673 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Puma Biotechnology by 17.2% in the fourth quarter. State Street Corp now owns 877,077 shares of the biopharmaceutical company’s stock worth $5,219,000 after buying an additional 128,419 shares during the period. 61.29% of the stock is currently owned by hedge funds and other institutional investors.

About Puma Biotechnology

Puma Biotechnology, Inc is a late‐stage biopharmaceutical company dedicated to the development and commercialization of targeted therapies for oncology patients. Founded in 2010 and headquartered in Los Angeles, California, the company focuses on advancing molecularly defined cancer treatments that address significant unmet medical needs.

The company’s lead product is neratinib, marketed under the brand name Nerlynx in the United States. Neratinib is an irreversible small‐molecule tyrosine kinase inhibitor designed to target the HER2 receptor, and it received FDA approval in 2017 for extended adjuvant treatment of early‐stage HER2-positive breast cancer.